In recent years the scope for near perfect price discrimination, particularly in the digital economy, appears to have grown. This raises a question over how those jurisdictions in which exploitative price discrimination is an offence will respond. In contrast, the risk of price discrimination...

This paper explores excessive prices at the intersection between competition law and regulated sectors such as pharma. It was prepared as a background note for the OECD Competition Committee roundtable on “Excessive pricing in pharmaceuticals”, which took place in November 2018.

Online personalised pricing is a form of price discrimination that involves charging different prices to different consumers, often based on a consumer’s personal data. Policymakers are currently discussing ways to protect consumers from potential adverse effects of personalised pricing. One...

Pharmaceutical policy making raises particular challenges in reconciling key objectives for health policy, such as ensuring affordable access to the latest effective drugs, with other important policy considerations, such as providing support to a valuable national industry. Unusually among...

The consumer prices dataset is a subset of the Main Economic Indicators (MEI) database comprising predominantly monthly statistics on all items, food, energy and services as well as harmonised consumer prices for all items. Data are expressed as percentage change or index (2010 = 100) and are...

This dataset contains monthly comparative price levels (CPL) which are defined as the ratios of purchasing power parities (PPPs) for private final consumption expenditure to exchange rates. They provide measures of differences in price levels between countries. The monthly PPPs used to derive...